CASE STUDY'A Pharmaceutical Company Would Never Do This' STU BORMAN, C&EN WASHINGTONAt the University of Pittsburgh, researchers have been working on a combinatorial project that drug firms would consider too much of a gamble, according to the project's principal investigator, chemistry professor Peter Wipf. He described the project--the pursuit of analogs of the natural product curacin A as potential anticancer lead compounds--at the recent ACS ProSpectives conference on combinatorial chemistry.----->http://pubs.acs.org/cen/coverstory/8045/8045combinatorial1b.html;o)
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS